JamesR.BosscherMD

Oncology • Neptune, NJ

Gynecologic Cancer

Obstetrics/Gynecology - Gynecologic Oncology Meridian Medical Group - Faculty Practice

Join to view full profile

Dr. Bosscher is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bosscher's full profile

Already have an account?

Office
19 Davis Avenue
Neptune, NJ 07753
Phone+1 732-897-7944

Fax+1 732-922-8264

Summary

Dr. James Bosscher is a renowned Oncologist currently retired but was last based in Neptune, NJ, specializing in gynecologic cancer. He completed his education and residency in Obstetrics and Gynecology at the National Capital Consortium, Tripler Army Medical Centre, and Wayne State University School of Medicine. His expertise lies in gynecologic oncology, reflected in his numerous publications in the field of gynecologic oncology that have been cited multiple times. Dr. Bosscher has also led and participated in a number of clinical trials aimed at improving patient outcomes. His contributions to healthcare were celebrated when he received the CMS Meaningful Use Stage 1 Certification from the EpicCare Ambulatory EMR, Epic Systems Corporation, between 2011 and 2013.

Education & Training

National Capital ConsortiumResidency, Obstetrics and Gynecology, 1988 - 1993
Tripler Army Medical CenterResidency, Obstetrics and Gynecology, 1979 - 1983
Wayne State University School of MedicineClass of 1979

Certifications & Licensure

NJ State Medical License 2015 - 2025
OH State Medical License 2015 - 2017
PA State Medical License 2010 - 2016
MO State Medical License 2000 - 2012
KY State Medical License 1993 - 2000
MD State Medical License 1988 - 1994
American Board of Obstetrics and Gynecology Obstetrics & Gynecology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
Recruiting
Phase 3
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2009 Aug 17
Active, not recruiting
Phase 3
Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer Start of enrollment: 2012 Jun 01
Unknown status
Not Applicable
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Start of enrollment: 2009 Nov 01
Terminated
Phase 3
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Start of enrollment: 2010 Oct 12
Active, not recruiting
Phase 3
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12
Active, not recruiting
Phase 3
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 3
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy Start of enrollment: 2010 Nov 01
Completed
Phase 2
Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms Start of enrollment: 2011 Jul 01
Completed
Phase 3
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia Start of enrollment: 2012 Jun 18
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

9 citations
Intestinal surgery performed on gynecologic cancer patients
Danny Barnhill, David Doering, Steven Remmenga, James Bosscher, John D. Nash
Gynecologic Oncology. 1991-01-01
67 citations
Sunitinib Malate in the treatment of recurrent or persistent uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study
Martee L. Hensley, Michael W. Sill, Dennis R. Scribner, Jubilee Brown, Robert Debernardo
Gynecologic Oncology. 2009-12-01
80 citations
Squamous Cell Carcinoma Antigen: Clinical Utility in Squamous Cell Carcinoma of the Uterine Cervix
Jo-Ann N. Bolli, David L. Doering, James R. Bosscher, Thomas G. Day, C V Rao
Gynecologic Oncology. 1994-11-01

Press Mentions

Meridian Cancer Care Team Welcomes James Bosscher, M.DFebruary 12th, 2016